Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.

Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara N, Bais C.

Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11590-5. doi: 10.1073/pnas.1109029108. Epub 2011 Jun 27.


A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS.

Cancer Cell. 2010 Apr 13;17(4):362-75. doi: 10.1016/j.ccr.2009.12.049.


Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.

Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10625-30. Epub 2007 Jun 6.


Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels.

Yao VJ, Ozawa MG, Varner AS, Kasman IM, Chanthery YH, Pasqualini R, Arap W, McDonald DM.

Cancer Res. 2006 Mar 1;66(5):2639-49.


Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma.

Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, McDonald DM.

Cancer. 2005 Nov 15;104(10):2104-15.


Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors.

Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A, Baluk P, Favre CJ, Jeffry U, Murray R, McDonald DM.

Am J Pathol. 2005 Jul;167(1):193-211.


Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels.

Magnussen A, Kasman IM, Norberg S, Baluk P, Murray R, McDonald DM.

Cancer Res. 2005 Apr 1;65(7):2712-21.

Supplemental Content

Loading ...
Support Center